Therapies for improving muscle function in neuromuscular disorders.
Muscle atrophy or wasting is a loss of muscle tissue resulting from disease or lack of use. This review examines recent pharmacologic or nutrition interventions for ameliorating wasting and improving muscle function in neuromuscular disorders. The information has application for treating the muscular dystrophies, cancer cachexia, weightlessness, immobilization, denervation, and disuse atrophy.
Lynch
G S
GS
Department of Physiology, The University of Melbourne, Victoria, Australia. g.lynch@physiology.unimelb.edu.au
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000420:Albuterol / Q000627:therapeutic use; D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003401:Creatine / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D005973:Glutamine / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D018482:Muscle, Skeletal / Q000187:drug effects; D020388:Muscular Dystrophy, Duchenne / Q000628:therapy*; D009468:Neuromuscular Diseases / Q000503:physiopathology / Q000628:therapy*; D013739:Testosterone / Q000627:therapeutic use; D014631:Valerates
D000276:Adjuvants, Immunologic; D000318:Adrenergic beta-Agonists; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D016207:Cytokines; D005938:Glucocorticoids; D014631:Valerates; D005973:Glutamine; D019382:Human Growth Hormone; C004961:beta-hydroxyisovaleric acid; D013739:Testosterone; D003687:Dehydroepiandrosterone; D007334:Insulin-Like Growth Factor I; D003401:Creatine; D000420:Albuterol